<html><head></head><body><h1>Fam-Trastuzumab Deruxtecan-nxki</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
<b>Chemical Name:</b> Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-l-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3¢,4¢:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl], disulfide with humanized monoclonal antibody k-chain, anti-(human ERBB2 [epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340]), immunoglobulin G1-k dimer<br/>
<b>CAS Number:</b> 1826843-81-5<br/>
<b>Brands:</b> Enhertu</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li>
<li>FAQ</li></ul><h3>Warning</h3><ul>Interstitial Lung Disease (ILD)
<li>
<p>Serious, sometimes fatal, ILD, including pneumonitis, reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Monitor for new or worsening respiratory symptoms indicative of ILD (e.g., dyspnea, cough, fever).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If ILD occurs, temporary interruption, dosage reduction, or permanent discontinuance of therapy may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration and also see ILD under Cautions.)</p>
</li>
</ul><p>Serious, sometimes fatal, ILD, including pneumonitis, reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor for new or worsening respiratory symptoms indicative of ILD (e.g., dyspnea, cough, fever).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If ILD occurs, temporary interruption, dosage reduction, or permanent discontinuance of therapy may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration and also see ILD under Cautions.)</p><ul>Embryofetal Toxicity
<li>
<p>Risk of embryofetal death or birth defects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients of risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise women of childbearing potential to use effective contraception during therapy and for at least 7 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise men who are partners of such women to use effective contraception during therapy and for at least 4 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p>
</li>
</ul><p>Risk of embryofetal death or birth defects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients of risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise women of childbearing potential to use effective contraception during therapy and for at least 7 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise men who are partners of such women to use effective contraception during therapy and for at least 4 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p><h2>Introduction</h2><p>Antineoplastic agent; an anti-human epidermal growth factor receptor type 2 (anti-<i>HER2</i>) antibody-drug conjugate consisting of a humanized IgG<sub>1</sub> monoclonal antibody (trastuzumab) covalently linked to a type I DNA topoisomerase inhibitor DXd (an exatecan derivative).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Fam-Trastuzumab Deruxtecan-nxki</h2><h3>Breast Cancer</h3><p>Treatment of unresectable or metastatic breast cancer in patients whose tumors overexpress the <i>HER2</i> protein and who have received at least 2 prior anti-<i>HER2</i>-based regimens for metastatic disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Efficacy determined based on objective response rate and duration of response; clinical benefit not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Continued approval may be contingent on verification and description of clinical benefit in confirmatory studies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Fam-Trastuzumab Deruxtecan-nxki Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Do <i>not</i> substitute fam-trastuzumab deruxtecan-nxki (Enhertu<sup></sup>) for or use with trastuzumab (Herceptin<sup></sup>) or ado-trastuzumab emtansine (Kadcyla<sup></sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Exercise extra care to ensure accuracy of preparation and administration of fam-trastuzumab deruxtecan-nxki.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Consult specialized references for procedures for proper handling and disposal of antineoplastic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If infusion-related reactions occur, slow or interrupt IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If severe infusion-related reactions occur, permanently discontinue drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Do <i>not</i> substitute fam-trastuzumab deruxtecan-nxki (Enhertu<sup></sup>) for or use with trastuzumab (Herceptin<sup></sup>) or ado-trastuzumab emtansine (Kadcyla<sup></sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Exercise extra care to ensure accuracy of preparation and administration of fam-trastuzumab deruxtecan-nxki.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult specialized references for procedures for proper handling and disposal of antineoplastic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If infusion-related reactions occur, slow or interrupt IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If severe infusion-related reactions occur, permanently discontinue drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><ul>
<li>
<p>Obtain through designated specialty pharmacies and specialty distributors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Obtain through designated specialty pharmacies and specialty distributors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>For solution compatibility information, see Compatibility under Stability.</p><p>Administer by IV infusion through polyolefin or polybutadiene administration sets with a 0.2 or 0.22-<i>μ</i>m polyethersulfone (PES) or polysulfone filter.</p><p><i>Do not administer by rapid IV injection (e.g., IV push or bolus).</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Fam-trastuzumab deruxtecan-nxki powder for injection must be reconstituted and diluted prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Unopened vials of fam-trastuzumab deruxtecan-nxki injection should be stored at 2–8°C in the original carton for protection from light; vials should <i>not</i> be frozen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not mix or administer through the same IV line with other drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstitute vial containing 100 mg of fam-trastuzumab deruxtecan-nxki with 5 mL of sterile water for injection to provide a solution containing 20 mg/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Gently swirl vial to ensure dissolution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do <i>not</i> shake reconstituted solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstituted solution should be clear and colorless to light yellow, and free of visible particulates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dilute appropriate dose in a PVC or polyolefin infusion bag containing 100 mL of 5% dextrose injection; do <i>not</i> dilute in 0.9% sodium chloride injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Mix the diluted solution by gentle inversion; do <i>not</i> shake.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard any partially used vials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initial dose: Administer over 90 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Subsequent doses: Administer over 30 minutes (if first infusion is well tolerated).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>5.4 mg/kg every 3 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Continue until disease progression or until unacceptable toxicity occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a dose is missed or delayed, do <i>not</i> wait until the next scheduled dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Adjust dosage schedule to maintain a 3-week interval between doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Temporary interruption, dosage reduction, and/or permanent discontinuance may be necessary for adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If dosage reduction is required, reduce dosage as described in Table 1.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not re-escalate dosage following dosage reduction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage Reduction Level</p><p>Dosage Reduction after Recovery from Toxicity (Initial Dosage = 5.4 mg/kg every 3 weeks)</p><p>First</p><p>Resume at 4.4 mg/kg every 3 weeks</p><p>Second</p><p>Resume at 3.2 mg/kg every 3 weeks</p><p>Third</p><p>Permanently discontinue drug</p><p>If an adverse reaction occurs, modify dosage accordingly (see Table 2).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adverse Reaction and Severity</p><p>Dosage Modification</p><p><b>Pulmonary Toxicity</b></p><p>Grade 1 asymptomatic ILD or pneumonitis</p><p>Withhold therapy and consider initiating corticosteroid therapy (see ILD under Cautions)</p><p>If ILD or pneumonitis resolves in ≤28 days of onset, resume therapy at same dosage</p><p>If ILD or pneumonitis does not resolve within 28 days of onset, resume therapy at a reduced dosage by one dose level (see Table 1)</p><p>Grade 2 or greater symptomatic ILD or pneumonitis</p><p>Permanently discontinue therapy and promptly initiate corticosteroid therapy (see ILD under Cautions)</p><p><b>Neutropenia</b></p><p>Grade 3 (absolute neutrophil count [ANC] 500–1000/mm<sup>3</sup> )</p><p>Withhold therapy; when neutropenia improves to grade 2 or less, resume therapy at same dosage</p><p>Grade 4 (ANC &lt;500/mm<sup>3</sup> )</p><p>Withhold therapy; when neutropenia improves to grade 2 or less, resume therapy at reduced dosage by one dose level (see Table 1)</p><p>Febrile neutropenia (ANC &lt;1000/mm<sup>3</sup> with fever &gt;38.3ºC or ≥38ºC for &gt;1 hour)</p><p>Withhold therapy; when febrile neutropenia resolves, resume therapy at reduced dosage by one dose level (see Table 1)</p><p><b>Left Ventricular Dysfunction</b></p><p>LVEF &gt;45% with an absolute decrease from baseline of 10–20%</p><p>Continue therapy at same dosage</p><p>LVEF decreases to 40–45% with an absolute decrease from baseline of &lt;10%</p><p>Continue therapy at same dosage and reassess left ventricular function within 3 weeks.</p><p>LVEF decreases to 40–45% with an absolute decrease from baseline of 10–20%</p><p>Withhold therapy and reassess left ventricular function within 3 weeks</p><p>If LVEF improves to within 10% of baseline, resume therapy at same dosage</p><p>If LVEF does not improve to within 10% of baseline, permanently discontinue therapy</p><p>LVEF decreases to &lt;40% or absolute decrease from baseline of &gt;20%</p><p>Withhold therapy and reassess left ventricular function within 3 weeks</p><p>If LVEF &lt;40% or absolute decrease from baseline of &gt;20% is confirmed, permanently discontinue therapy</p><p>Symptomatic CHF</p><p>Permanently discontinue therapy</p><h3>Prescribing Limits</h3><p>Dosage &lt;3.2 mg/kg every three weeks not recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Mild (total bilirubin concentration not exceeding upper limit of normal [ULN] with AST concentration exceeding ULN, or total bilirubin concentration exceeding ULN, but ≤1.5 times ULN, with any AST concentration) or moderate (total bilirubin concentration &gt;1.5 times the ULN, but ≤3 times the ULN, with any AST concentration) hepatic impairment: No dosage adjustment required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Impairment under Cautions.)</p><p>Severe hepatic impairment (total bilirubin concentration &gt;3 times ULN, but ≤10 times ULN, with any AST concentration): No specific dosage recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mild (Cl<sub>cr</sub> 60–89 mL/minute) or moderate (Cl<sub>cr</sub> 30–59 mL/minute) renal impairment: No dosage adjustment required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Cautions.)</p><p>Severe renal impairment (Cl<sub>cr</sub> &lt;30 mL/minute): No specific dosage recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No specific dosage recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Use under Cautions.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Fam-Trastuzumab Deruxtecan-nxki</h2><h3>Contraindications</h3><ul>
<li>
<p>Manufacturer states none known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Manufacturer states none known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Severe, life-threatening, or fatal ILD, including pneumonitis, reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor patients for pulmonary symptoms indicative of ILD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If ILD is suspected, evaluate patients using radiographic imaging and consider consultation with a pulmonologist.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If asymptomatic (grade 1) ILD occurs, consider systemic corticosteroid therapy (≥0.5 mg/kg of prednisolone daily [or equivalent])&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; followed by gradual tapering (e.g., over 4 weeks) of the corticosteroid dosage once symptoms improve.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If symptomatic (grade 2 or greater) ILD occurs, initiate systemic corticosteroid therapy (≥1 mg/kg of prednisolone daily [or equivalent])&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; followed by gradual tapering (e.g., over 4 weeks) of the corticosteroid dosage once symptoms improve.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Interruption of therapy, dosage reduction, or permanent discontinuance of therapy may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration.)</p><p>May cause fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Oligohydramnios, fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death observed following administration of an anti-<i>HER2</i> antibody to pregnant women in postmarketing experience.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>DXd (derivative of exatecan) may cause embryotoxic and fetotoxic effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Verify pregnancy status prior to initiation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Women of reproductive potential should use effective contraceptive methods while receiving the drug and for ≥7 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Men who are partners of such women should use effective contraceptive methods while receiving the drug and for ≥4 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If used during pregnancy or if patient becomes pregnant during therapy, apprise of potential fetal hazard.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If used during pregnancy or within 7 months prior to conception, monitor for oligohydramnios.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If oligohydramnios occurs, perform fetal testing appropriate for gestational age and according to standards of care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe neutropenia, including febrile neutropenia reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor CBCs at baseline, prior to each dose, and as clinically indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Interruption of therapy or dosage reduction may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration.)</p><p>Anti-<i>HER2</i> antibodies, including fam-trastuzumab deruxtecan, are associated with decreases in LVEF.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not studied in patients with a baseline LVEF &lt;50%, symptomatic CHF, or conditions that could impair left ventricular function (e.g., serious cardiac arrhythmia or unstable angina requiring therapy within 28 days of study enrollment, history of MI within 6 months of study enrollment).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Assess LVEF prior to initiation of therapy, regularly during therapy, and as clinically indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If LVEF occurs, interruption of therapy or discontinuance of therapy may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reassessment of LVEF may be needed within 3 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration.)</p><p>Potential for immunogenicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Data insufficient to determine whether antibody formation affects efficacy or safety.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Neutralizing antibodies not assessed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Results of animal studies suggest fam-trastuzumab deruxtecan may impair male fertility.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p><p>If used during pregnancy or within 7 months prior to conception, monitor for oligohydramnios.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If oligohydramnios occurs, perform fetal testing appropriate for gestational age and according to standards of care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether fam-trastuzumab deruxtecan is distributed into milk, affects nursing infants, or affects milk production.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue nursing during therapy and for 7 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In clinical trials, 26% of patients were ≥65 years of age and 5% were ≥75 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; No overall differences in efficacy observed between geriatric patients and younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Grade 3 or 4 adverse reactions occurred more frequently in geriatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pharmacokinetics not affected by mild hepatic impairment (total bilirubin concentration not exceeding ULN with AST concentration exceeding ULN, or total bilirubin concentration exceeding ULN, but ≤1.5 times the ULN, with any AST concentration); no dosage adjustment necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Special Populations under Pharmacokinetics.)</p><p>Not studied in patients with moderate or severe (total bilirubin concentration &gt;1.5 times ULN with any AST concentration) hepatic impairment; closely monitor patients with moderate hepatic impairment for signs of toxicity from the type I DNA topoisomerase inhibitor DXd.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pharmacokinetics not affected by mild (Cl<sub>cr</sub> 60–89 mL/minute) or moderate (Cl<sub>cr</sub> 30–59 mL/minute) renal impairment; no dosage adjustment required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Special Populations under Pharmacokinetics.)</p><p>Not studied in patients with severe renal impairment (Cl<sub>cr</sub> &lt;30 mL/minute).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, neutropenia, diarrhea, leukopenia, cough, thrombocytopenia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Fam-Trastuzumab Deruxtecan-nxki</h2><p>DXd, the type I DNA topoisomerase inhibitor component of the antibody-drug conjugate, primarily metabolized by CYP3A4.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>DXd does not inhibit CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A or induce CYP isoenzymes 1A2, 2B6, or 3A.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>DXd does not inhibit organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, organic anion transport protein (OATP) 1B1, OATP1B3, multidrug and toxin extrusion (MATE) transporter 1, MATE2K, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or bile salt export pump (BSEP) at clinically relevant concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; DXd is a substrate of OATP1B1, OATP1B3, MATE2K, P-gp, multidrug resistance-associated protein (MRP) 1, and BCRP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Itraconazole</p><p>Increased AUC of fam-trastuzumab deruxtecan and DXd by 11 and 18%, respectively; not considered clinically meaningful&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ritonavir</p><p>Increased AUC of fam-trastuzumab deruxtecan and DXd by 19 and 22%, respectively; not considered clinically meaningful&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Fam-Trastuzumab Deruxtecan-nxki Pharmacokinetics</h2><h3>Absorption</h3><p>Systemic exposure of antibody-drug conjugate and free DXd are dose proportional over a dose range of 3.2–8 mg/kg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Steady-state concentrations achieved after 3 treatment cycles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Systemic accumulation of antibody-drug conjugate is approximately 35% following repeated administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mild hepatic impairment (total bilirubin concentration not exceeding ULN with AST concentration exceeding ULN, or total bilirubin concentration exceeding ULN, but ≤1.5 times ULN, with any AST concentration): No substantial effects on pharmacokinetics of antibody-drug conjugate or DXd.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Moderate hepatic impairment (total bilirubin concentration &gt;1.5 times ULN, but ≤3 times ULN, with any AST concentration): Pharmacokinetics not studied; increased exposure possible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe hepatic impairment (total bilirubin concentration &gt;3 times ULN, but ≤10 times ULN, with any AST concentration): Pharmacokinetics not studied.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mild (Cl<sub>cr</sub> of 60–89 mL/minute) or moderate (Cl<sub>cr</sub> of 30–59 mL/minute) renal impairment: No substantial effects on pharmacokinetics of antibody-drug conjugate or DXd.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe renal impairment (Cl<sub>cr</sub> &lt;30 mL/minute): Pharmacokinetics not studied.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Age (range: 23–96 years), race, sex, and body weight (range: 35–125 kg) do not have clinically important effects on pharmacokinetics of antibody-drug conjugate or DXd.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Not known whether fam-trastuzumab deruxtecan is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>DXd: Approximately 97%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Anti-<i>HER2</i> antibody: Expected to degrade into small peptides and amino acids via catabolic pathways.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>DXd: Metabolized by CYP3A4 in vitro.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antibody-drug conjugate: Approximately 5.7 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>DXd: Approximately 5.8 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>2–8°C in original carton for protection from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do <i>not</i> freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May store reconstituted drug in vial at 2–8°C for up to 24 hours after reconstitution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light; do <i>not</i> freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May store final diluted IV infusion solution at room temperature for ≤4 hours (including preparation and infusion time) or at 2–8°C for ≤24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Allow diluted solutions of the drug to reach room temperature prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do <i>not</i> freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dextrose 5% in water</p><p>Incompatible&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sodium chloride 0.9%</p><h2>Actions</h2><ul>
<li>
<p>An anti-<i>HER2</i> antibody (trastuzumab; a humanized IgG<sub>1</sub>) conjugated via a protease-cleavable maleimide tetrapeptide linker to the type I DNA topoisomerase inhibitor DXd (an exatecan derivative).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Resultant complex referred to as deruxtecan.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Antibody portion of fam-trastuzumab deruxtecan binds to extracellular domain of the <i>HER2</i> receptor on tumor cells;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; resultant complex internalized by cell and DXd releases following cleavage of the linker by lyososomal enzymes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; DXd binds to and stabilizes DNA topoisomerase 1 cleavable complexes, resulting in double-stranded breaks in DNA and apoptosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>High drug-to-antibody ratio (approximately 8 molecules of deruxtecan are attached to each molecule of antibody) compared with ado-trastuzumab emtansine (approximately 3–4 molecules of emtansine are attached to each molecule of antibody).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>An anti-<i>HER2</i> antibody (trastuzumab; a humanized IgG<sub>1</sub>) conjugated via a protease-cleavable maleimide tetrapeptide linker to the type I DNA topoisomerase inhibitor DXd (an exatecan derivative).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Resultant complex referred to as deruxtecan.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antibody portion of fam-trastuzumab deruxtecan binds to extracellular domain of the <i>HER2</i> receptor on tumor cells;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; resultant complex internalized by cell and DXd releases following cleavage of the linker by lyososomal enzymes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; DXd binds to and stabilizes DNA topoisomerase 1 cleavable complexes, resulting in double-stranded breaks in DNA and apoptosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>High drug-to-antibody ratio (approximately 8 molecules of deruxtecan are attached to each molecule of antibody) compared with ado-trastuzumab emtansine (approximately 3–4 molecules of emtansine are attached to each molecule of antibody).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of instructing patients to read the manufacturer's patient information (medication guide).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of severe or fatal ILD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately informing clinician if new or worsening respiratory symptoms occur (e.g., cough, shortness of breath, wheezing, fever).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of neutropenia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately informing clinician if fever or other signs of infection occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of left ventricular dysfunction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately informing clinicians if manifestations of left ventricular dysfunction (e.g., new or worsening shortness of breath, cough, fatigue, swelling of ankles or legs, abnormal heartbeat, dizziness, sudden weight gain, sudden loss of consciousness) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Necessity of advising women of childbearing potential to avoid pregnancy and to use effective contraceptive methods during and for ≥7 months following the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of advising men who are partners of such women that they should use effective methods of contraception during and for ≥4 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women informing clinician if they become pregnant during therapy or think they may be pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise pregnant women of potential risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising women to avoid breast-feeding during therapy and for 7 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of impaired male fertility.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of instructing patients to read the manufacturer's patient information (medication guide).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of severe or fatal ILD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately informing clinician if new or worsening respiratory symptoms occur (e.g., cough, shortness of breath, wheezing, fever).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of neutropenia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately informing clinician if fever or other signs of infection occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of left ventricular dysfunction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately informing clinicians if manifestations of left ventricular dysfunction (e.g., new or worsening shortness of breath, cough, fatigue, swelling of ankles or legs, abnormal heartbeat, dizziness, sudden weight gain, sudden loss of consciousness) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Necessity of advising women of childbearing potential to avoid pregnancy and to use effective contraceptive methods during and for ≥7 months following the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of advising men who are partners of such women that they should use effective methods of contraception during and for ≥4 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women informing clinician if they become pregnant during therapy or think they may be pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise pregnant women of potential risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising women to avoid breast-feeding during therapy and for 7 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of impaired male fertility.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Distribution of fam-trastuzumab deruxtecan-nxki is restricted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Restricted Distribution under Dosage and Administration.)</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>For Injection, for IV Infusion only</p><p>100 mg</p><p>Enhertu<sup></sup></p><p>Daiichi Sankyo (comarketed with AstraZeneca)</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions November 9, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. Daiichi Sankyo Inc. Enhertu<sup></sup> (fam-trastuzumab deruxtecan-nxki) injection for intravenous use prescribing information. Basking Ridge, NJ; 2019 Dec.</p><p>2. Modi S, Saura C, Yamashita T et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>N Engl J Med.</i>. 2020; 382:610-21. https://www.ncbi.nlm.nih.gov/pubmed/31825192</p><p>3. Tamura K, Tsurutani J, Takahashi S et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncol</i>. 2019; 20:816-26. https://www.ncbi.nlm.nih.gov/pubmed/31047803</p><p>4. Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug-Conjugates Beyond T-DM1 in Breast Cancer. <i>Int J Mol Sci . 20(5):111</i>. 2019; 20:1-17. https://www.ncbi.nlm.nih.gov/pubmed/31047803</p><p>5. Daiichi Sankyo Inc. Enhertu<sup></sup>: Distribution. From Enhertu<sup></sup>4U for US Health Care Professionals website. Accessed 2020 Mar 2. https://www.enhertu4u.com/hcp/distribution.html</p><p>6. Nakada T, Sugihara K, Jikoh T et al. The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. <i>Chem. Pharm. Bull</i> . 2019; 67:173-85. https://www.ncbi.nlm.nih.gov/pubmed/31047803</p><p>7. Sharma P. Major Strides in HER2 Blockade for Metastatic Breast Cancer. <i>N Engl J Med.</i>. 2020; 382:669-71.</p><p>8. US Food and Drug Administration. Center for Drug Evaluation and Research: Application number 761139Orig1s000: Multi-discipline review. 2019 Jun 11. From FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761139Orig1s000MultidisciplineR.pdf</p><p>9. Daiichi Sankyo Inc. Basking Ridge, NJ: Personal communication.</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Is Enhertu a chemotherapy drug? What's Enhertu used for?</li>
</ul><h2>More about fam-trastuzumab deruxtecan</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: HER2 inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fam-trastuzumab deruxtecan-nxki Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Breast Cancer, Metastatic</li>
<li>Stomach Cancer</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>